Key Points
- To evaluate the antithrombotic efficacy and bleeding risks of DX-9065a, a specific factor Xa inhibitor, in rat models of thrombosis.
- Administered DX-9065a intravenously (0.23 mg/kg and 2.33 mg/kg) or orally (23.3 mg/kg) to rats.
- Assessed antithrombotic effects in tissue thromboplastin-induced disseminated intravascular coagulation (TP-DIC) and arterio-venous (AV) shunt models, alongside bleeding time measurements.
- In the TP-DIC model, intravenous DX-9065a (0.23 mg/kg) suppressed platelet and fibrinogen consumption to 57% and 66%, respectively, and almost completely suppressed fibrin degradation product production.
- In the AV shunt model, thrombus formation was inhibited to 51% with 0.23 mg/kg intravenously and to 60% with 23.3 mg/kg orally.
- Intravenous administration of DX-9065a at 2.33 mg/kg did not alter bleeding time.
Structured PICO
Does DX-9065a inhibit thrombosis without affecting bleeding time in rat models of DIC and AV shunt?
PPopulationRat models of tissue thromboplastin-induced DIC (TP-DIC) and arterio-venous shunt (AV shunt)
IInterventionDX-9065a (specific factor Xa inhibitor) administered intravenously (0.23 mg/kg or 2.33 mg/kg) or orally (23.3 mg/kg)
OOutcomeAntithrombotic effects (platelet and fibrinogen consumption, thrombus formation) and bleeding timesurrogate
DX-9065a demonstrates antithrombotic efficacy without prolonging bleeding time in rat models, suggesting factor Xa inhibition is a promising therapeutic strategy.